Abstract
The cyclosaligenyl (cycloSal) derivatives of the monophosphates of three acyclic or carbocyclic guanosine analogues, for example, acyclovir (ACV), carbovir (CBV) and abacavir (ABC), were investigated for their activity against retrovirus (HIV, Moloney sarcoma virus) and herpes simplex virus (HSV) activity in cell culture. The extent of the antiviral potency of the prodrugs depended on the nature of the nucleoside, the substituent on the cycloSal moiety and the virus investigated. Most notably, and unlike the parent compound ACV, cycloSal-ACV monophosphate (MP) prodrugs retained pronounced activity against ACV-resistant (thymidine kinase-deficient) HSV-1 and also gained anti-HIV activity. While the cycloSal-CBVMP prodrugs did not show enhanced activity compared with the parent compound CBV, the cycloSal-ABCMP prodrugs afforded markedly increased potency against both HSV and HIV. Our data indicate that the cycloSal prodrug approach can be useful to deliver directly the MP derivatives of nucleoside analogues into the intact, virus-infected cells, thus improving and extending the antiviral potency and spectrum of the drugs against retro- and herpesvirus strains.
References
Jan 1, 1990·Annals of the New York Academy of Sciences·Y C ChengM C Starnes
May 1, 1980·The Journal of Infectious Diseases·E De ClercqD Shugar
Sep 29, 1995·Journal of Medicinal Chemistry·I LefebvreJ L Imbach
Dec 1, 1994·Antimicrobial Agents and Chemotherapy·J L MartinJ E Reardon
Nov 11, 1994·Journal of Medicinal Chemistry·D FarquharP P Saunders
Apr 15, 1994·Pharmacy World & Science : PWS·J Balzarini
May 10, 1996·Journal of Medicinal Chemistry·G ValetteJ L Imbach
Apr 12, 1996·Journal of Medicinal Chemistry·C McGuiganJ Balzarini
Jul 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·J BalzariniC McGuigan
Aug 14, 1996·Biochemical and Biophysical Research Communications·J BalzariniC McGuigan
Apr 3, 1998·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·J BalzariniH Thormar
May 23, 1998·Journal of Medicinal Chemistry·C MeierJ Balzarini
Jan 6, 1999·Antiviral Chemistry & Chemotherapy·C MeierP Wutzler
Feb 13, 1999·Journal of Medicinal Chemistry·A Q SiddiquiJ Balzarini
May 7, 1999·Journal of Medicinal Chemistry·C MeierJ Balzarini
May 7, 1999·Journal of Medicinal Chemistry·C MeierJ Balzarini
Nov 26, 1999·Molecular Pharmacology·J BalzariniC Meier
Oct 20, 2000·Molecular Pharmacology·J BalzariniC Meier
Nov 4, 2000·Medicinal Research Reviews·C R WagnerE J McIntee
Feb 6, 2002·Chembiochem : a European Journal of Chemical Biology·C MeierP Wutzler
Citations
Mar 6, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Christophe VanpouilleLeonid Margolis
May 5, 2016·Applied Biochemistry and Biotechnology·Suresh K ALokanatha Valluru
Dec 13, 2006·Nucleosides, Nucleotides & Nucleic Acids·Mariola Koszytkowska-StawińskaErik De Clercq
Sep 20, 2002·Antiviral Chemistry & Chemotherapy·Chris MeierJan Balzarini
Mar 27, 2004·Nucleosides, Nucleotides & Nucleic Acids·Chris MeierJan Balzarini
Sep 20, 2002·Antiviral Chemistry & Chemotherapy·Christian DuchoChris Meier
Feb 21, 2008·Antimicrobial Agents and Chemotherapy·Parmjeet RandhawaMatthews Bradley
Jan 16, 2021·Journal of Pharmaceutical Sciences·Maria Silvia Gurgel AssisAndré Luís Morais Ruela
May 20, 2021·Chemistry of Heterocyclic Compounds·Vladimir E Kataev, Bulat F Garifullin
May 26, 2004·Bioorganic & Medicinal Chemistry·T K VenkatachalamF M Uckun
Apr 22, 2004·Journal of the American Chemical Society·Mark D ErionPaul D Van Poelje
Mar 6, 2007·Journal of Medicinal Chemistry·Nicolas GischChris Meier